CD19 and neoplasm: Recent developments have led to the engineering of trispecific constructs that engage multiple tumor-associated antigens (e.g., CD19 and CD20) and/or costimulatory receptors (e.g., CD28 or CD2), enhancing cytotoxic potency and potentially mitigating antigen escape.